The cost of Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can vary based on several factors, including your insurance coverage. Coupons and drug savings ...
FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera (Reuters) - British drugmaker ...
GlaxoSmithKline is spinning the first DTC campaign this week for its crucial new COPD drug, Trelegy Ellipta, backed by a throwback soundtrack. The theme song reworks The Jackson 5’s hit tune “ABC," ...
With generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's ...
Trelegy Ellipta is not indicated for relief of acute bronchospasm or the treatment of asthma. Trelegy contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic ...
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an ...
GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that the FDA has granted approval to its medicine Trelegy Ellipta for a new asthma indication. The FDA has approved the triple ...
Shares of Theravance Biopharma, Inc. TBPH rallied 5.3% on positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”), the scientific committee of the European Medicines Agency ( ...
GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs have helped offset the impact of generics on its Advair blockbuster in the US. The ...
GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market. Top-line results ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Trelegy Ellipta, once-daily, single-inhaler triple therapy, for the new indication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback